Palisade Bio(PALI) - 2025 Q4 - Annual Report

Clinical Development - The company is advancing PALI-2108, a once-daily oral PDE4 inhibitor prodrug, towards a Phase 2 clinical study in ulcerative colitis (UC) to evaluate clinical remission response and pharmacodynamic biomarkers over 12 weeks [24]. - The Phase 1 clinical study of PALI-2108 has completed dosing of 89 subjects, with positive results reported for safety, tolerability, and pharmacokinetics [39]. - The exploratory Phase 1b cohort in fibrotic strictures of Crohn's disease (FSCD) is expected to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics over a 14-day treatment period [40]. - The company plans to submit Investigational New Drug Applications (IND) to the FDA for Phase 2 studies in UC and CD in 2026 [42]. - The company has commenced a Phase 1 clinical trial for PALI-2108 in Canada, with positive results reported from various cohorts [196]. - The lead clinical product candidate, PALI-2108, may face regulatory approval challenges due to potential undesirable side effects [211]. - Clinical trials could be suspended or terminated if unacceptable severity and prevalence of side effects are revealed, adversely affecting business and financial condition [212]. - Regulatory approval for PALI-2108 requires significant development, clinical testing, and substantial financial investment, with no assurance of success [214]. Market Overview - The market for ulcerative colitis (UC) treatments was valued at approximately $7.3 billion in 2021 and is expected to grow to over $9.5 billion by 2031, reflecting a compound annual growth rate (CAGR) of approximately 2.78% [43]. - Diagnosed incident cases of UC in the eight major markets (8MM) are projected to increase from 160,122 cases in 2021 to 168,467 cases by 2031, with an annual growth rate (AGR) of 0.52% [43]. - The global market for Crohn's disease (CD) treatments was valued at $13.9 billion in 2022 and is projected to grow to approximately $25.5 billion by 2032, with a CAGR of approximately 6% [45]. - Diagnosed incident cases of CD in the 8MM are expected to increase from 118,885 cases in 2022 to 122,175 cases by 2032, reflecting an AGR of 0.28% [44]. Regulatory Environment - The FDA requires extensive monitoring and auditing of all clinical activities and data during all phases of clinical development [87]. - Phase 3 clinical trials, referred to as pivotal studies, typically require two adequate and well-controlled trials for NDA approval, although one may suffice with supporting evidence [88]. - The FDA reviews an NDA within 60 days to determine if it is substantially complete before accepting it for filing [100]. - The FDA may impose restrictions on product distribution and require post-marketing clinical trials for approved products [105]. - The FDA has performance goals under the PDUFA, aiming to review standard NDAs in ten months and priority NDAs in six months [106]. - The FDA has various expedited programs to facilitate the development and review of drugs for serious or life-threatening conditions [107]. - IND safety reports must be submitted within seven calendar days for unexpected fatal or life-threatening adverse reactions [89]. - Compliance with cGMP regulations is mandatory for manufacturers to ensure consistent production of pharmaceutical products [94]. - The FDA may refuse to file any NDA deemed incomplete or not properly reviewable at the time of submission [100]. - The FDA may require a REMS to ensure the safe use of a product candidate if deemed necessary [102]. - The Fast Track program allows expedited review for new drugs and biologics intended to treat serious conditions, with increased FDA interactions during development [108]. - Priority review designation can reduce FDA review time to six months from the standard ten months for drugs showing significant safety or effectiveness improvements [110]. - Accelerated approval may be granted for drugs that provide meaningful advantages over existing therapies, based on surrogate endpoints or earlier clinical endpoints [111]. - Breakthrough therapy designation offers intensive guidance and expedited development for drugs showing substantial improvement over existing therapies [112]. - The FDA's Commissioner's National Priority Voucher pilot program aims to accelerate reviews for products addressing key national health priorities, with targeted review completion within 1-2 months [113]. - Post-approval requirements include annual user fees and compliance with cGMP regulations, emphasizing quality control and safety [116]. Intellectual Property - The company has exclusive rights to one pending patent application in the U.S. and six pending applications internationally related to PALI-2108 [73]. - A Notice of Allowance for the patent covering PALI-2108 was issued by the China National Intellectual Property Administration in July 2025 [73]. - The expected expiration date of the patent related to LB1148 is 2031, excluding any adjustments or extensions [77]. - The Hatch-Waxman Amendments allow for patent term extensions of up to five years for drugs lost during development and FDA review, with a maximum total patent life of 14 years [128]. - New Chemical Entity (NCE) exclusivity provides five years of non-patent marketing exclusivity for the first approved drug containing an NCE [134]. - A drug may obtain a three-year exclusivity for a new indication if new clinical trials were essential for approval [135]. - Orphan drug exclusivity grants seven years of market protection for drugs approved for rare diseases affecting fewer than 200,000 individuals in the U.S. [138]. - Pediatric exclusivity can extend marketing protection by six months if pediatric research is conducted as requested by the FDA [139]. Financial and Operational Considerations - The company has not yet established a commercial organization or distribution capabilities for potential product candidates [55]. - The company relies on third parties for clinical supply and manufacturing of its product candidates, including PALI-2108 [56][60]. - LBS engages a network of third-party CDMOs and CMOs to ensure quality and compliance in drug development and manufacturing [58]. - The company expects to have sufficient capital to fund operations through major clinical development milestones, including a Phase 2 primary efficacy readout of PALI-2108 for UC expected in the second half of 2027 [207]. - The company faces challenges in patient enrollment for clinical trials, which could delay or prevent trial completion [205]. - The company must navigate evolving data privacy laws, such as the California Consumer Privacy Act (CCPA), which may increase compliance costs and potential liabilities [164]. - The company faces risks related to data security and privacy regulations, which are rapidly changing and could impose significant operational costs [161]. - The implementation of cost containment measures may adversely affect the company's ability to generate revenue and achieve profitability [154]. Competitive Landscape - LBS faces competition from large pharmaceutical companies and emerging biotech firms in the IBD treatment space, impacting market share [65][66]. - The company’s product candidates, if approved, would compete with established therapies such as TNF antibodies and JAK inhibitors for moderate-to-severe IBD [69][70]. Legislative and Policy Changes - The U.S. healthcare system is undergoing significant reforms aimed at controlling costs and improving access, which may impact the profitability of pharmaceutical products [146]. - The Affordable Care Act (ACA) includes provisions that affect pharmaceutical manufacturers, such as Medicaid rebates and annual fees on branded drugs, which could influence revenue streams [147]. - The Inflation Reduction Act (IRA) mandates price negotiations for high Medicare spend drugs starting in 2026, potentially affecting pricing strategies and revenue [149]. - Legislative changes, including the establishment of the "Department of Government Efficiency," may lead to operational disruptions and delays in FDA approvals, impacting product development timelines [150]. - The current administration's executive orders focus on lowering drug prices and increasing competition, which may create additional pricing pressures for pharmaceutical companies [151]. - State-level regulations are increasingly controlling drug pricing and reimbursement, which could lead to reduced revenue from both government and private payors [154]. - Compliance with government pricing programs, such as the Medicaid Drug Rebate program and the 340B Drug Pricing program, imposes financial obligations on manufacturers that could affect profitability [155][156]. Subsidiaries and Agreements - The company has two wholly owned subsidiaries, with one, Suzhou Neuralstem Biopharmaceutical Co., Ltd., currently in the process of dissolution [182]. - The company issued contingent value rights (CVRs) entitling holders to 80% of net proceeds from the sale or licensing of legacy technology, with no payments made to CVR holders to date [183]. - The company has an exclusive license for NSI-189 assets, with a purchase option that was early exercised by Alto Neuroscience [184]. - Alto is required to pay up to $4.5 million upon achieving certain development and regulatory approval milestones for ALTO-100, with a maximum aggregate payment of $5.0 million under the ATA [186]. - A milestone payment of $1.5 million will be due from Alto upon the enrollment of a patient in a Phase 3 clinical trial of ALTO-100 [187]. - The University of Michigan will bear 100% of the costs for patent filing and maintenance related to NSI-532.IGF-1, with the company receiving 50% of net revenues from licensing [188].